Finoriq research workspace

Aclaris Therapeutics, Inc. (ACRS) Historical Metrics

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering. Review ACRS valuation ratios, fundamentals, and filing metrics on Finoriq.

Company Snapshot

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Company

Aclaris Therapeutics, Inc. (ACRS)

Ticker

ACRS

Market Cap

$782.8M

Latest Price

$5.605

Industry

Biotech & Pharma

Open insider transactions

Aclaris Therapeutics, Inc. (ACRS) Current Valuation Metrics

Static valuation preview for Aclaris Therapeutics, Inc. (ACRS). Market data retrieved 2026-07-09. Filing currency USD.

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.